Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
Frontiers Media S.A.,
2021-10-01T00:00:00Z.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sailkapena: |
A1234.567 |
|---|---|
| Alea 1 | Eskuragarri |